PATH Partners With GSK on Malaria Vaccine

6/6/11

PATH, the Seattle-based global health nonprofit, said it has formed a collaboration with Netherlands-based Crucell and London-based GlaxoSmithKline to develop a next-generation malaria vaccine. The effort will bring together two vaccine approaches in an attempt to improve upon Glaxo’s RTS,S, a vaccine that has shown an ability to protect about half of people who get immunized against malaria. The collaboration will focus on using a single dose of a Crucell vaccine candidate, followed by two doses of RTS,S, in what is known as the “prime-boost” strategy to trigger immune defenses. Terms of the partnership weren’t disclosed.

By posting a comment, you agree to our terms and conditions.